Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5

被引:49
作者
Lin, Yinling [1 ]
Kwon, Taewoo [1 ]
Polo, John [1 ]
Zhu, Yi-Fei [1 ]
Coates, Stephen [1 ]
Crawford, Kevin [1 ]
Dong, Christine [1 ]
Wininger, Mark [1 ]
Hall, John [1 ]
Selby, Mark [1 ]
Coit, Doris [1 ]
Medina-Selby, Angelica [1 ]
McCoin, Colin [1 ]
Ng, Philip [1 ]
Drane, Debbie [1 ]
Chien, David [1 ]
Han, Jang [1 ]
Vajdy, Michael [1 ]
Houghtont, Michael [1 ]
机构
[1] Novartis Vaccine & Diagnost Inc, Emeryville, CA 94608 USA
关键词
D O I
10.1128/JVI.02743-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Broad, multispecific CD4(+) and CD8(+) T-cell responses to the hepatitis C virus (HCV), as well as virus-cross-neutralizing antibodies, are associated with recovery from acute infection and may also be associated in chronic HCV patients with a favorable response to antiviral treatment. In order to recapitulate all of these responses in an ideal vaccine regimen, we have explored the use of recombinant HCV polypeptides combined with various Th1-type adjuvants and replication-defective alphaviral particles encoding HCV proteins in various prime/boost modalities in BALB/c mice. Defective chimeric alphaviral particles derived from the Sindbis and Venezuelan equine encephalitis viruses encoding either the HCV envelope glycoprotein gpE1/gpE2 heterodimer (E1E2) or nonstructural proteins 3, 4, and 5 (NS345) elicited strong CD8(+) T-cell responses but low CD4(+) T helper responses to these HCV gene products. In contrast, recombinant E1E2 glycoproteins adjuvanted with MF59 containing a CpG oligonucleotide elicited strong CD4(+) T helper responses but no CD8(+) T-cell responses. A recombinant NS345 polyprotein also stimulated strong CD4(+) T helper responses but no CD8(+) T-cell responses when adjuvanted with Iscomatrix containing CpG. Optimal elicitation of broad CD4(+) and CD8(+) T-cell responses to E1E2 and NS345 was obtained by first priming with Th1-adjuvanted proteins and then boosting with chimeric, defective alphaviruses expressing these HCV genes. In addition, this prime/boost regimen resulted in the induction of anti-E1E2 antibodies capable of cross-neutralizing heterologous HCV isolates in vitro. This vaccine formulation and regimen may therefore be optimal in humans for protection against this highly heterogeneous global pathogen.
引用
收藏
页码:7492 / 7503
页数:12
相关论文
共 64 条
  • [21] KOO G, 1989, SCIENCE, V244, P362
  • [22] Effect of immune globulin on the prevention of experimental hepatitis C virus infection
    Krawczynski, K
    Alter, MJ
    Tankersley, DL
    Beach, M
    Robertson, BH
    Lambert, S
    Kuo, G
    Spelbring, JE
    Meeks, E
    Sinha, S
    Carson, DA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (04) : 822 - 828
  • [23] CPG MOTIFS IN BACTERIAL-DNA TRIGGER DIRECT B-CELL ACTIVATION
    KRIEG, AM
    YI, AK
    MATSON, S
    WALDSCHMIDT, TJ
    BISHOP, GA
    TEASDALE, R
    KORETZKY, GA
    KLINMAN, DM
    [J]. NATURE, 1995, 374 (6522) : 546 - 549
  • [24] Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-Class CpG oligodeoxynucleotide TLR9 agonist
    Krieg, AM
    Efler, SM
    Wittpoth, M
    Al Adhami, MJ
    Davis, HL
    [J]. JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : 460 - 471
  • [25] Cross-genotype immunity to hepatitis C virus
    Lanford, RE
    Guerra, B
    Chavez, D
    Bigger, C
    Brasky, KA
    Wang, XH
    Ray, SC
    Thomas, DL
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (03) : 1575 - 1581
  • [26] Medical progress: Hepatitis C virus infection.
    Lauer, GM
    Walker, BD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) : 41 - 52
  • [27] Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection
    Lavillette, D
    Morice, Y
    Germanidis, G
    Donot, P
    Soulier, A
    Pagkalos, E
    Sakellariou, G
    Intrator, L
    Bartosch, B
    Pawlotsky, JM
    Cosset, FL
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (10) : 6023 - 6034
  • [28] Analysis of successful immune responses in persons infected with hepatitis C virus
    Lechner, F
    Wong, DKH
    Dunbar, PR
    Chapman, R
    Chung, RT
    Dohrenwend, P
    Robbins, G
    Phillips, R
    Klenerman, P
    Walker, BD
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (09) : 1499 - 1512
  • [29] COMPARTMENTALIZATION OF T-LYMPHOCYTES TO THE SITE OF DISEASE - INTRAHEPATIC CD4+ T-CELLS SPECIFIC FOR THE PROTEIN-NS4 OF HEPATITIS-C VIRUS IN PATIENTS WITH CHRONIC HEPATITIS-C
    MINUTELLO, MA
    PILERI, P
    UNUTMAZ, D
    CENSINI, S
    KUO, G
    HOUGHTON, M
    BRUNETTO, MR
    BONINO, F
    ABRIGNANI, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (01) : 17 - 25
  • [30] A novel viral system for generating antigen-specific T cells
    Moran, TP
    Collier, M
    McKinnon, KP
    Davis, NL
    Johnston, RE
    Serody, JS
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (05) : 3431 - 3438